CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 15, 2014--
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to
developing potentially transformative gene therapies for severe genetic
and orphan diseases, today announced the pricing of an underwritten
public offering of 2,650,000 shares of its common stock at a public
offering price of $85.00 per share, before underwriting discounts. In
addition, bluebird bio has granted the underwriters a 30-day option to
purchase from it up to an additional 397,500 shares of common stock.
BofA Merrill Lynch and Cowen and Company are acting as joint
book-running managers of the proposed offering. SunTrust Robinson
Humphrey, Wedbush PacGrow Life Sciences and Roth Capital Partners are
acting as co-managers. The offering is expected to close on or about
December 19, 2014, subject to customary closing conditions.
bluebird bio anticipates the aggregate net proceeds from the offering
will be approximately $211.4 million, after deducting the underwriting
discount and estimated offering expenses payable by bluebird bio, but
excluding any exercise of the underwriters’ option. bluebird bio intends
to use the net proceeds of this offering primarily to advance its
clinical studies in CCALD (childhood cerebral adrenoleukodystrophy),
beta-thalassemia major and sickle cell disease. The balance will be used
for general and administrative expenses, potential future development
programs, early-stage research and development and other general
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was previously
filed with the Securities and Exchange Commission (SEC). A preliminary
prospectus supplement relating to and describing the terms of the
offering was filed with the SEC on December 15, 2014. The final
prospectus supplement relating to the offering will be filed with the
SEC and will be available on the SEC’s web site at www.sec.gov.
When available, copies of the final prospectus supplement and the
accompanying prospectus relating to these securities may also be
obtained by contacting one of the following: BofA Merrill Lynch, 222
Broadway, New York, NY 10038, Attn: Prospectus Department, or via email,
or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long
Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or jurisdiction.
About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing
potentially transformative gene therapies for severe genetic and orphan
diseases. bluebird bio has two clinical-stage programs in development.
The most advanced product candidate, Lenti-D, is in a Phase 2/3 study,
the Starbeam Study, for the treatment of childhood cerebral
adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder
affecting young boys. The next most advanced product candidate,
LentiGlobin, is currently in two Phase 1/2 studies for the treatment of
beta-thalassemia major, one in the United States, Australia and Thailand
(the Northstar Study) and one in France (HGB-205). The Phase 1/2 HGB-205
study also allows enrollment of patient(s) with sickle cell disease, and
bluebird bio has initiated a separate U.S. sickle cell disease trial
(HGB-206). bluebird bio also has an early-stage chimeric antigen
receptor-modified T cell (CAR-T) program for oncology in collaboration
with Celgene Corporation.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
Washington and Paris, France.
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the terms, timing and completion of the proposed
offering; the use of proceeds of the offering; and bluebird bio’s
existing product candidates and research programs. Any forward-looking
statements are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks and uncertainties
related to market conditions and satisfaction of customary closing
conditions related to the proposed public offering, that the preliminary
results from our clinical trials will not continue or be repeated in our
ongoing clinical trials, the risk that previously conducted studies
involving similar product candidates will not be repeated or observed in
ongoing or future studies involving current product candidates, the risk
of cessation or delay of any of the ongoing or planned clinical studies
and/or our development of our product candidates, the risk of a delay in
the enrollment of patients in our clinical studies, the risk that our
collaboration with Celgene will not continue or will not be successful,
and the risk that any one or more of our product candidates will not be
successfully developed and commercialized. For a discussion of other
risks and uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors” in
our most recent quarterly report on Form 10-Q, as well as discussions of
potential risks, uncertainties, and other important factors in our
subsequent filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release, and
bluebird bio undertakes no duty to update this information unless
required by law.
Source: bluebird bio, Inc.
Pure Communications, Inc.
Dan Budwick, 973-271-6085